Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Amends Biomarker Pact with Veridex

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that it has renewed and amended an existing licensing agreement with Veridex for use of certain DNA methylation biomarkers for colorectal cancer and prostate cancer screening.

Under the revised pact, Veridex, a Johnson & Johnson company, has received non-exclusive rights for worldwide laboratory service testing using MDxHealth's DNA methylation biomarkers. The licensed technology may be used for blood-based detection of colorectal cancer and for tissue- and urine-based detection of prostate cancer.

In return, Liege, Belgium-based MDxHealth will receive from Veridex milestone payments and royalties on net sales. Financial and other terms were not disclosed.

The new agreement replaces an older pact between the firms that had granted Veridex exclusive rights to certain MDxHealth DNA methylation biomarkers.

Jan Groen, CEO of MDxHealth, said that the new agreement "greatly simplifies our contractual obligations and at the same time it could potentially provide revenues from future royalty streams from prostate and colorectal cancer screening applications developed by Veridex."

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.